We are live on ! Find out more
ENVB icon

Enveric Biosciences
ENVB

10 hedge funds and large institutions have $631K invested in Enveric Biosciences in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

65% more capital invested

Capital invested by funds: $382K → $631K (+$249K)

0.01% less ownership

Funds ownership: 0.06% → 0.05% (-0.01%)

9% less funds holding

Funds holding: 11 → 10 (-1)

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

Holders
10
Holders Change
-1
Holders Change %
-9.09%
% of All Funds
0.16%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
1
Reduced
2
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$46.2K
2
Citadel Advisors
Citadel Advisors
Florida
+$37.5K
3
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$12.2K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$1.46K

Top Sellers

Rank Fund Capital Flow
1
AI
AdvisorShares Investments
Maryland
-$115K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$21K
3
VF
Virtu Financial
New York
-$18K
4
TRCT
Tower Research Capital (TRC)
New York
-$15.6K
5
UBS Group
UBS Group
Switzerland
-$14.6K
Name Holding Trade Value Shares
Change 		Change in
Stake
AI
1
AdvisorShares Investments
Maryland
$338K -$115K -237 -30%
BlackRock
2
BlackRock
New York
$99.7K – – –
Renaissance Technologies
3
Renaissance Technologies
New York
$58K +$46.2K +95 New
Citadel Advisors
4
Citadel Advisors
Florida
$47K +$37.5K +77 New
Vanguard Group
5
Vanguard Group
Pennsylvania
$42.2K +$1.46K +3 +4%
TRCT
6
Tower Research Capital (TRC)
New York
$28.1K -$15.6K -32 -41%
Acadian Asset Management
7
Acadian Asset Management
Massachusetts
$15K +$12.2K +25 New
Royal Bank of Canada
8
Royal Bank of Canada
Ontario, Canada
$1K – – –
Group One Trading
9
Group One Trading
Illinois
$920 – – –
Bank of America
10
Bank of America
North Carolina
$340 – – –
National Bank of Canada
11
National Bank of Canada
Quebec, Canada
$232 – – –
UBS Group
12
UBS Group
Switzerland
$182 -$14.6K -30 Closed
Wells Fargo
13
Wells Fargo
California
$101 – – –
Morgan Stanley
14
Morgan Stanley
New York
$3 – – –
Susquehanna International Group
15
Susquehanna International Group
Pennsylvania
– -$21K -69 Closed
VF
16
Virtu Financial
New York
– -$18K -59 Closed
Osaic Holdings
17
Osaic Holdings
Arizona
– -$249 -1 Closed

ENVB Hedge Fund Activity: Q2 2023 in Review

10 of the 6,371 institutional investors tracked by Wall St. Rank reported a position in Enveric Biosciences (ENVB) for Q2 2023, worth a combined $631K — up 65% from $382K a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of ENVB and 3 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 1 added.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $46.2K. The largest seller was AdvisorShares Investments, cutting an estimated $115K.

  • 10 institutional investors held Enveric Biosciences (ENVB) as of Q2 2023, down from 11 in Q1 2023.
  • Funds reported $631K of Enveric Biosciences stock for Q2 2023, up 65% quarter-over-quarter.
  • 3 funds opened new Enveric Biosciences positions in Q2 2023 and 4 closed out, a net change of -1 holder.
  • The largest Enveric Biosciences buyer in Q2 2023 was Renaissance Technologies, an estimated $46.2K added.
  • The largest Enveric Biosciences seller in Q2 2023 was AdvisorShares Investments, an estimated $115K sold.

Based on aggregated 13F filings for Q2 2023.